Advanced search
Publication Cover
Modern Rheumatology Volume 24, 2014 - Issue 4
Journal homepage
1,574
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial

Takahiko KurasawaDepartment of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan;Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan
,
Hayato NagasawaDepartment of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
,
Mayumi KishimotoSanten Pharmaceutical Co., Ltd. Kita-ku, Osaka, Japan
,
Koichi AmanoDepartment of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
,
Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan
&
Hideto KamedaDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Shinjuku-ku, Tokyo, Japan;Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University, Meguro-ku, Tokyo, JapanCorrespondence[email protected]
Pages 561-566 | Received 26 Jun 2013, Accepted 12 Sep 2013, Published online: 05 Nov 2013

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Satoshi Ito, Shunsuke Sakai, Yoichi Kurosawa, Daisuke Kobayashi, Ryo Okabayashi, Asami Abe, Hiroshi Otani, Kiyoshi Nakazono, Akira Murasawa, Ichiei Narita & Hajime Ishikawa. (2021) The long-term observation of patients with rheumatoid arthritis who achieved a biological disease-modifying antirheumatic drug-free condition with adalimumab. Modern Rheumatology 31:4, pages 919-923.
Read now

Articles from other publishers (7)

Michael M. Ward, Nima Madanchi, Ali Yazdanyar, Nehal R. Shah & Florina Constantinescu. (2023) Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review. Arthritis Research & Therapy 25:1.
Crossref
Pablo A. Nogara, Cláudia S. Oliveira, Meire E. Pereira, Marco Bortoli, Laura Orian, Michael Aschner & João B.T. Rocha. 2022. Redox Chemistry and Biology of Thiols. Redox Chemistry and Biology of Thiols 643 677 .
Hideto Kameda, Ayako Hirata, Takaharu Katagiri, Yuto Takakura, Yuki Inoue, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina & Takehisa Ogura. (2021) Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. Scientific Reports 11:1.
Crossref
Satoshi Ito, Daisuke Kobayashi, Eriko Hasegawa, Chinatsu Takai, Tetsuya Nemoto, Hyunho Lee, Asami Abe, Hiroshi Otani, Hajime Ishikawa, Akira Murasawa, Ichiei Narita & Kiyoshi Nakazono. (2019) An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients. Internal Medicine 58:4, pages 511-519.
Crossref
Lise M. Verhoef, Lieke Tweehuysen, Marlies E. Hulscher, Bruno Fautrel & Alfons A. den Broeder. (2017) bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatology and Therapy 4:1, pages 1-24.
Crossref
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young & Allan Wailoo. (2016) Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation. Health Technology Assessment 20:35, pages 1-610.
Crossref
Kazuki Yoshida, Mitsumasa Kishimoto, Helga Radner, Kazuo Matsui, Masato Okada, Yukihiko Saeki, Daniel H. Solomon & Shigeto Tohma. (2016) Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology 55:2, pages 286-290.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.